Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Multiple Luteinized Follicle Cysts of the Ovary in a Patient With a Pituitary Adenoma: Report of a Case and Review of the Literature.

Lebok P, Zuna RE, Holman LL, Young RH.

Int J Gynecol Pathol. 2018 Oct 24. doi: 10.1097/PGP.0000000000000555. [Epub ahead of print]

PMID:
30358638
2.

Cytologic patterns of cervical adenocarcinomas with emphasis on factors associated with underdiagnosis.

Conrad RD, Liu AH, Wentzensen N, Zhang RR, Dunn ST, Wang SS, Schiffman M, Gold MA, Walker JL, Zuna RE.

Cancer Cytopathol. 2018 Nov;126(11):950-958. doi: 10.1002/cncy.22055. Epub 2018 Oct 23.

3.

A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.

Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Mestdagh P, Gunaratne PH, Yau C, Bowlby R, Robertson AG, Tiezzi DG, Wang C, Cherniack AD, Godwin AK, Kuderer NM, Rader JS, Zuna RE, Sood AK, Lazar AJ, Ojesina AI, Adebamowo C, Adebamowo SN, Baggerly KA, Chen TW, Chiu HS, Lefever S, Liu L, MacKenzie K, Orsulic S, Roszik J, Shelley CS, Song Q, Vellano CP, Wentzensen N; Cancer Genome Atlas Research Network, Weinstein JN, Mills GB, Levine DA, Akbani R.

Cancer Cell. 2018 Apr 9;33(4):690-705.e9. doi: 10.1016/j.ccell.2018.03.014. Epub 2018 Apr 2.

4.

Integrated Molecular Characterization of Uterine Carcinosarcoma.

Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, Zuna RE, Robertson G, Laird PW, Kucherlapati R, Mills GB; Cancer Genome Atlas Research Network, Weinstein JN, Zhang J, Akbani R, Levine DA.

Cancer Cell. 2017 Mar 13;31(3):411-423. doi: 10.1016/j.ccell.2017.02.010.

5.

A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.

Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA 3rd, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D.

Gynecol Oncol. 2017 May;145(2):291-297. doi: 10.1016/j.ygyno.2017.02.040. Epub 2017 Mar 10.

6.

Distribution of cell types differs in Papanicolaou tests of squamous cell carcinomas and adenocarcinomas.

Conrad R, Wentzensen N, Zhang RR, Wang S, Schiffman M, Gold M, Walker J, Zuna RE.

J Am Soc Cytopathol. 2017 Jan - Feb;6(1):10-15. doi: 10.1016/j.jasc.2016.08.003. Epub 2016 Aug 11.

PMID:
31042628
7.

Adenocarcinoma of the cervix involving the fallopian tube mucosa: report of a case.

Deel CD, Allen RA, Holman LL, Zuna RE.

Diagn Pathol. 2016 Aug 17;11(1):77. doi: 10.1186/s13000-016-0529-8.

8.

Comparison of Colposcopic Impression Based on Live Colposcopy and Evaluation of Static Digital Images.

Liu AH, Gold MA, Schiffman M, Smith KM, Zuna RE, Dunn ST, Gage JC, Walker JL, Wentzensen N.

J Low Genit Tract Dis. 2016 Apr;20(2):154-61. doi: 10.1097/LGT.0000000000000194.

9.

Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.

Patterson AM, Kaabinejadian S, McMurtrey CP, Bardet W, Jackson KW, Zuna RE, Husain S, Adams GP, MacDonald G, Dillon RL, Ames H, Buchli R, Hawkins OE, Weidanz JA, Hildebrand WH.

Mol Cancer Ther. 2016 Feb;15(2):313-22. doi: 10.1158/1535-7163.MCT-15-0658. Epub 2015 Dec 30.

10.

Chromosomal copy number alterations and HPV integration in cervical precancer and invasive cancer.

Bodelon C, Vinokurova S, Sampson JN, den Boon JA, Walker JL, Horswill MA, Korthauer K, Schiffman M, Sherman ME, Zuna RE, Mitchell J, Zhang X, Boland JF, Chaturvedi AK, Dunn ST, Newton MA, Ahlquist P, Wang SS, Wentzensen N.

Carcinogenesis. 2016 Feb;37(2):188-196. doi: 10.1093/carcin/bgv171. Epub 2015 Dec 9. No abstract available.

11.

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods.

Castro FA, Koshiol J, Quint W, Wheeler CM, Gillison ML, Vaughan LM, Kleter B, van Doorn LJ, Chaturvedi AK, Hildesheim A, Schiffman M, Wang SS, Zuna RE, Walker JL, Dunn ST, Wentzensen N.

BMC Infect Dis. 2015 Nov 25;15:544. doi: 10.1186/s12879-015-1281-5.

12.

Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling.

den Boon JA, Pyeon D, Wang SS, Horswill M, Schiffman M, Sherman M, Zuna RE, Wang Z, Hewitt SM, Pearson R, Schott M, Chung L, He Q, Lambert P, Walker J, Newton MA, Wentzensen N, Ahlquist P.

Proc Natl Acad Sci U S A. 2015 Jun 23;112(25):E3255-64. doi: 10.1073/pnas.1509322112. Epub 2015 Jun 8.

13.

Multiple biopsies and detection of cervical cancer precursors at colposcopy.

Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C, Dunn ST, Zhang R, Moxley K, Bishop E, Tenney M, Nugent E, Graubard BI, Wacholder S, Schiffman M.

J Clin Oncol. 2015 Jan 1;33(1):83-9. doi: 10.1200/JCO.2014.55.9948. Epub 2014 Nov 24.

14.

Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer.

Zhao L, Wentzensen N, Zhang RR, Dunn ST, Gold MA, Wang SS, Schiffman M, Walker JL, Zuna RE.

Cancer Cytopathol. 2014 Sep;122(9):694-701. doi: 10.1002/cncy.21443. Epub 2014 May 28.

15.

Evaluation of clinical performance of a novel urine-based HPV detection assay among women attending a colposcopy clinic.

Sahasrabuddhe VV, Gravitt PE, Dunn ST, Robbins D, Brown D, Allen RA, Eby YJ, Smith KM, Zuna RE, Zhang RR, Gold MA, Schiffman M, Walker JL, Castle PE, Wentzensen N.

J Clin Virol. 2014 Aug;60(4):414-7. doi: 10.1016/j.jcv.2014.04.016. Epub 2014 May 2.

16.

A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study.

Campos SM, Brady WE, Moxley KM, O'Cearbhaill RE, Lee PS, DiSilvestro PA, Rotmensch J, Rose PG, Thaker PH, O'Malley DM, Hanjani P, Zuna RE, Hensley ML.

Gynecol Oncol. 2014 Jun;133(3):537-41. doi: 10.1016/j.ygyno.2014.02.036. Epub 2014 Mar 1. Erratum in: Gynecol Oncol. 2014 Dec;135(3):624.

17.

Phase II trial of vaginal cuff brachytherapy followed by chemotherapy in early stage endometrial cancer patients with high-intermediate risk factors.

Landrum LM, Nugent EK, Zuna RE, Syzek E, Mannel RS, Moore KN, Walker JL, McMeekin DS.

Gynecol Oncol. 2014 Jan;132(1):50-4. doi: 10.1016/j.ygyno.2013.11.005. Epub 2013 Nov 9.

PMID:
24219982
18.

Comparison of human papillomavirus detections in urine, vulvar, and cervical samples from women attending a colposcopy clinic.

Sahasrabuddhe VV, Gravitt PE, Dunn ST, Brown D, Allen RA, Eby YJ, Smith K, Zuna RE, Zhang RR, Gold MA, Schiffman M, Walker JL, Castle PE, Wentzensen N.

J Clin Microbiol. 2014 Jan;52(1):187-92. doi: 10.1128/JCM.01623-13. Epub 2013 Nov 6.

19.

Evaluation of a multiplex panel of immune-related markers in cervical secretions: a methodologic study.

Koshiol J, Sklavos M, Wentzensen N, Kemp T, Schiffman M, Dunn ST, Wang SS, Walker JL, Safaeian M, Zuna RE, Hildesheim A, Pfeiffer RM, Pinto LA.

Int J Cancer. 2014 Jan 15;134(2):411-25. doi: 10.1002/ijc.28354. Epub 2013 Jul 30.

20.

Chromosomal gains measured in cytology samples from women with abnormal cervical cancer screening results.

Luhn P, Houldsworth J, Cahill L, Schiffman M, Castle PE, Zuna RE, Dunn ST, Gold MA, Walker J, Wentzensen N.

Gynecol Oncol. 2013 Sep;130(3):595-600. doi: 10.1016/j.ygyno.2013.06.005. Epub 2013 Jun 13.

21.

The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.

Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN.

Gynecol Oncol. 2013 Aug;130(2):377-82. doi: 10.1016/j.ygyno.2013.04.054. Epub 2013 Apr 28.

PMID:
23632208
22.

Reproducibility of linear array for human papillomavirus genotyping.

Koshiol J, Dunn ST, Walker JL, Zuna RE, Schiffman M, Sherman ME, Gold MA, Allen RA, Zhang R, Wang SS, Wentzensen N.

J Clin Microbiol. 2013 Feb;51(2):625-8. doi: 10.1128/JCM.03036-12. Epub 2012 Nov 28.

23.

The role of co-factors in the progression from human papillomavirus infection to cervical cancer.

Luhn P, Walker J, Schiffman M, Zuna RE, Dunn ST, Gold MA, Smith K, Mathews C, Allen RA, Zhang R, Wang S, Wentzensen N.

Gynecol Oncol. 2013 Feb;128(2):265-70. doi: 10.1016/j.ygyno.2012.11.003. Epub 2012 Nov 10.

24.

Tubal ligation frequency in Oklahoma women with cervical cancer.

Mathews CA, Stoner JA, Wentzensen N, Moxley KM, Tenney ME, Tuller ER, Myers T, Landrum LM, Lanneau G, Zuna RE, Gold MA, Wang SS, Walker JL.

Gynecol Oncol. 2012 Nov;127(2):278-82. doi: 10.1016/j.ygyno.2012.07.119. Epub 2012 Jul 31.

25.

Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.

Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, Allen RA, Zhang R, Dunn ST, Walker JL, Schiffman M.

Clin Cancer Res. 2012 Aug 1;18(15):4154-62. doi: 10.1158/1078-0432.CCR-12-0270. Epub 2012 Jun 6.

26.

Heterogeneity of high-grade cervical intraepithelial neoplasia related to HPV16: implications for natural history and management.

Wentzensen N, Walker J, Schiffman M, Yang HP, Zuna RE, Dunn ST, Allen RA, Zhang R, Sherman M, Gold MA, Wang SS.

Int J Cancer. 2013 Jan 1;132(1):148-54. doi: 10.1002/ijc.27577. Epub 2012 Apr 30.

27.

Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16.

van der Marel J, Quint WG, Schiffman M, van de Sandt MM, Zuna RE, Dunn ST, Smith K, Mathews CA, Gold MA, Walker J, Wentzensen N.

Int J Cancer. 2012 Sep 15;131(6):E946-53. doi: 10.1002/ijc.27532. Epub 2012 Apr 16.

28.

Human papillomavirus load measured by Linear Array correlates with quantitative PCR in cervical cytology specimens.

Wentzensen N, Gravitt PE, Long R, Schiffman M, Dunn ST, Carreon JD, Allen RA, Gunja M, Zuna RE, Sherman ME, Gold MA, Walker JL, Wang SS.

J Clin Microbiol. 2012 May;50(5):1564-70. doi: 10.1128/JCM.06240-11. Epub 2012 Feb 15.

29.

Clinical and pathological heterogeneity of cervical intraepithelial neoplasia grade 3.

Yang HP, Zuna RE, Schiffman M, Walker JL, Sherman ME, Landrum LM, Moxley K, Gold MA, Dunn ST, Allen RA, Zhang R, Long R, Wang SS, Wentzensen N.

PLoS One. 2012;7(1):e29051. doi: 10.1371/journal.pone.0029051. Epub 2012 Jan 13.

30.

HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer.

Zuna RE, Tuller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, Dunn ST, Gold MA, Wang SS, Walker J, Schiffman M.

Infect Agent Cancer. 2011 Oct 28;6:19. doi: 10.1186/1750-9378-6-19.

31.

Accuracy of cervical specimens obtained for biomarker studies in women with CIN3.

Wentzensen N, Zuna RE, Sherman ME, Gold MA, Schiffman M, Dunn ST, Jeronimo J, Zhang R, Walker J, Wang SS.

Gynecol Oncol. 2009 Dec;115(3):493-6. doi: 10.1016/j.ygyno.2009.09.001. Epub 2009 Sep 20.

32.

Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants.

Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA, Zhang R, Sherman ME, Wacholder S, Walker J, Wang SS.

Int J Cancer. 2009 Nov 1;125(9):2151-8. doi: 10.1002/ijc.24528.

33.

Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population.

Zuna RE, Moore WE, Shanesmith RP, Dunn ST, Wang SS, Schiffman M, Blakey GL, Teel T.

Int J Cancer. 2009 Dec 1;125(11):2609-13. doi: 10.1002/ijc.24706.

34.

Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.

Wang SS, Zuna RE, Wentzensen N, Dunn ST, Sherman ME, Gold MA, Schiffman M, Wacholder S, Allen RA, Block I, Downing K, Jeronimo J, Carreon JD, Safaeian M, Brown D, Walker JL.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):113-20. doi: 10.1158/1055-9965.EPI-08-0591.

35.

Human papillomavirus 16 E5 induces bi-nucleated cell formation by cell-cell fusion.

Hu L, Plafker K, Vorozhko V, Zuna RE, Hanigan MH, Gorbsky GJ, Plafker SM, Angeletti PC, Ceresa BP.

Virology. 2009 Feb 5;384(1):125-34. doi: 10.1016/j.virol.2008.10.011. Epub 2008 Nov 28.

36.

Grading the severity of cervical neoplasia based on combined histopathology, cytopathology, and HPV genotype distribution among 1,700 women referred to colposcopy in Oklahoma.

Wentzensen N, Schiffman M, Dunn ST, Zuna RE, Walker J, Allen RA, Zhang R, Sherman ME, Wacholder S, Jeronimo J, Gold MA, Wang SS.

Int J Cancer. 2009 Feb 15;124(4):964-9. doi: 10.1002/ijc.23969.

37.

Evaluation of linear array human papillomavirus genotyping using automatic optical imaging software.

Jeronimo J, Wentzensen N, Long R, Schiffman M, Dunn ST, Allen RA, Walker JL, Gold MA, Zuna RE, Sherman ME, Wacholder S, Wang SS.

J Clin Microbiol. 2008 Aug;46(8):2759-65. doi: 10.1128/JCM.00188-08. Epub 2008 Jun 11.

38.

Cervical dysplasia among women over 35 years of age.

Moore KN, Bannon RJ, Lanneau GS, Zuna RE, Walker JL, Gold MA.

Am J Obstet Gynecol. 2008 Nov;199(5):471.e1-5. doi: 10.1016/j.ajog.2008.03.048. Epub 2008 May 19.

PMID:
18486088
39.

Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc.

Ju T, Lanneau GS, Gautam T, Wang Y, Xia B, Stowell SR, Willard MT, Wang W, Xia JY, Zuna RE, Laszik Z, Benbrook DM, Hanigan MH, Cummings RD.

Cancer Res. 2008 Mar 15;68(6):1636-46. doi: 10.1158/0008-5472.CAN-07-2345. Erratum in: Cancer Res. 2008 Apr 15;68(8):3076.

40.
41.
42.

Worldwide genomic diversity of the high-risk human papillomavirus types 31, 35, 52, and 58, four close relatives of human papillomavirus type 16.

Calleja-Macias IE, Villa LL, Prado JC, Kalantari M, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Chu TY, Cubie HA, Cuschieri K, von Knebel-Doeberitz M, Martins CR, Sanchez GI, Bosch FX, Munoz N, Bernard HU.

J Virol. 2005 Nov;79(21):13630-40.

43.

Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18.

Prado JC, Calleja-Macias IE, Bernard HU, Kalantari M, Macay SA, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Ortiz-Lopez R, Barrera-Saldaña HA, Cubie HA, Cuschieri K, von Knebel-Doeberitz M, Sanchez GI, Bosch FX, Villa LL.

Virology. 2005 Sep 15;340(1):95-104.

45.

Papillomavirus subtypes are natural and old taxa: phylogeny of human papillomavirus types 44 and 55 and 68a and -b.

Calleja-Macias IE, Kalantari M, Allan B, Williamson AL, Chung LP, Collins RJ, Zuna RE, Dunn ST, Ortiz-Lopez R, Barrera-Saldaña HA, Cubie HA, Cuschieri K, Villa LL, Bernard HU.

J Virol. 2005 May;79(10):6565-9.

47.
48.
49.

Papillary adenocarcinoma of unknown primary in a young woman: a clinicopathologic correlation conference from the University of Oklahoma College of Medicine.

Gold MA, Tassone S, Huard D, Zuna RE.

J Okla State Med Assoc. 1999 Nov;92(11):529-34. No abstract available.

PMID:
10608092
50.

Columnar cells in smears from pseudomyxoma peritonei.

Gu M, Zuna RE.

Diagn Cytopathol. 1997 Feb;16(2):182-3. Review. No abstract available.

PMID:
9067115

Supplemental Content

Support Center